---
layout: default
title: Alpha -Tocopherol Ascorbic Acid Biotin Calcium Car
parent: 僅模型預測 (L5)
nav_order: 249
evidence_level: L5
indication_count: 0
---

# Alpha -Tocopherol Ascorbic Acid Biotin Calcium Car
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Vitamin/Mineral + Omega-3 Complex: Insufficient Data for Repurposing Analysis

## One-Sentence Summary

This candidate is a 13-component nutritional supplement combining vitamins, minerals, and omega-3 fatty acids (DHA/EPA), with no current market authorization in Taiwan and no defined approved indication.
The TxGNN model returned **no predicted indications** for this submission, as multi-component combinations cannot be mapped to a single DrugBank identifier required for graph-based prediction.
Without model output or an established original indication, a standard repurposing evaluation cannot be completed at this stage.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not established — no Taiwan approval records found |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction unavailable; no supporting studies identified) |
| Taiwan Market Status | ✗ Not Marketed |
| Number of Licenses | 0 |
| Recommended Decision | Hold |

---

## Why No Prediction Was Generated

This submission contains **13 distinct active pharmaceutical ingredients** spanning three pharmacological categories:

**Vitamins**
- Alpha-Tocopherol (Vitamin E)
- Ascorbic Acid (Vitamin C)
- Biotin (Vitamin B7)
- Cholecalciferol (Vitamin D3)
- Cyanocobalamin (Vitamin B12)
- Folic Acid (Vitamin B9)
- Pyridoxine (Vitamin B6)

**Minerals**
- Calcium Carbonate
- Ferrous Fumarate (Iron)
- Magnesium Oxide
- Potassium Iodide

**Omega-3 Fatty Acids**
- Doconexent (DHA — Docosahexaenoic acid)
- Icosapent (EPA — Eicosapentaenoic acid)

The TxGNN model operates on **single-entity DrugBank identifiers**. A fixed-dose combination product containing 13 ingredients cannot be assigned a unified DrugBank ID, which prevents the model from constructing a knowledge graph embedding and generating repurposing candidates. This is a known structural limitation of graph-based repurposing pipelines when applied to multi-ingredient formulas.

Based on the ingredient profile — particularly Folic Acid, DHA, Iron, Iodine, and Vitamin D3 — this combination is highly consistent with a **prenatal or perinatal nutritional supplement**. However, no approved indication is on record for this specific formulation in Taiwan, and no international regulatory reference was identified during the query window.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN pipeline cannot process multi-component combinations without a unified DrugBank ID, and no approved indication or safety documentation is available to support a repurposing baseline assessment.

**To proceed, the following is needed:**

- **Clarify intended use**: Confirm whether this combination is intended as a prenatal supplement, general multivitamin, or a condition-specific nutritional therapy, to provide clinical context for subsequent evaluation
- **Decompose and run individual predictions**: Submit key pharmacologically active components separately — particularly Doconexent (DHA), Icosapent (EPA), and Folic Acid — which each hold individual DrugBank IDs and can be processed by TxGNN independently
- **Identify international authorizations**: Search FDA (US), EMA, or other major regulators for approved products with a similar composition to establish indication reference and safety baseline
- **Obtain package insert**: Retrieve product labeling from TFDA or an equivalent authority to complete the safety gap (DG001) and establish contraindications and warnings
- **Resolve DrugBank mapping (DG002)**: Since `drugbank_id` is null, conduct a manual or API-assisted mapping for each individual ingredient to enable mechanism-of-action analysis
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

